Cytoskeletal drugs

Cytoskeletal drugs are small molecules that interact with the cytoskeletal proteins actin or tubulin. These drugs affect the cytoskeleton in one of three main ways: stabilizing cytoskeletal filaments, preventing the polymerization of protein monomers, or promoting the depolymerization of existing filaments.

Drugs that target microtubules, such as paclitaxel (taxol), are often used in chemotherapy for the treatment of cancer. ^[1] In contrast, drugs that target actin have limited clinical use due to severe off-target effects but remain valuable tools in cellular research.

Mechanisms of action

Cytoskeletal drugs can interfere with the normal dynamics of actin filaments and microtubules through several mechanisms.

Stabilization

Some drugs bind to and stabilize existing cytoskeletal polymers, preventing their depolymerization. Notable examples include taxol, which stabilizes microtubules, and phalloidin, which stabilizes actin filaments.

Inhibition of polymerization

Other drugs bind to free monomers and prevent them from polymerizing. Cytochalasin D, for instance, binds to actin monomers, while colchicine prevents the polymerization of microtubules.

Promotion of depolymerization

Certain drugs enhance the disassembly of already formed polymers. Demecolcine acts by promoting the depolymerization of microtubules.

Some drugs exhibit multiple effects. Latrunculin, for example, both prevents actin polymerization and enhances the rate of filament depolymerization.

Microtubule-targeting drugs

Drugs that target microtubules are frequently used in the clinic, primarily as anticancer agents in chemotherapy. ^[1] By disrupting microtubule dynamics, these drugs interfere with mitosis in rapidly dividing cancer cells. Examples include:

• Paclitaxel (taxol), which stabilizes microtubules and halts mitosis. ^[2]
• Vinblastine, nocodazole, and colchicine, which prevent the polymerization of tubulin monomers. ^{[1] [3] [4]}
• Demecolcine, which actively depolymerizes formed microtubules. ^[1]
• Rotenone, which prevents polymerization and is used as a pesticide. ^[5]

Actin-targeting drugs

The clinical use of actin-targeting drugs in animals is limited by a lack of specificity, as they cannot distinguish between different forms of actin (e.g., muscle vs. cytoskeletal). This leads to unacceptable off-target effects. However, these compounds are useful research tools for understanding the cell's internal machinery. For example, phalloidin conjugated with a fluorescent probe can be used to visualize actin filaments in fixed cell samples.

A cancer cell that was fixed and stained with phalloidin to visualize the actin cytoskeleton.

Depolymerizing agents

Cytochalasin D and latrunculin both promote the depolymerization of actin filaments but through different mechanisms. When added to live cells, they disassemble the actin cytoskeleton and inhibit cell movements like locomotion. ^[6]

• Cytochalasin D , a fungal alkaloid, binds to the (+) end of F-actin and blocks the addition of new actin subunits. ^[7]
• Latrunculin , a toxin secreted by sponges, binds to and sequesters G-actin monomers, preventing their addition to a filament end. ^[6]

Stabilizing agents

In contrast to the above, other toxins stabilize actin filaments.

• Jasplakinolide, a toxin from sponges, binds to and stabilizes actin dimers by enhancing nucleation. ^[6] This lowers the critical concentration required to form filaments. ^{[8] [9]}
• Phalloidin , a phallotoxin from the Amanita phalloides mushroom, prevents filament depolymerization by binding between F-actin subunits and locking them together. This paralyzes the cell, leading to cell death. ^[6]

Toxicity of phallotoxins

Phallotoxins are isolated from A. phalloides, commonly known as the "death cap" mushroom, which has been involved in fatal cases of mushroom poisoning. ^[10] Ingestion of the mushroom most commonly affects the liver and kidneys, causing symptoms that can include jaundice and seizures, ultimately resulting in death within hours. Three classes of toxins are found in A. phalloides: amatoxins, phallotoxins, and virotoxins. Like phallotoxins, virotoxins also interact with actin to prevent filament depolymerization, disrupting cytoskeletal function and paralyzing susceptible cells. ^[10]

Summary table

The following table summarizes the targets and effects of several common cytoskeletal drugs.

Drug Name	Target cytoskeletal component	Effect	Applications
Colchicine [11]	Microtubule	Prevents polymerization	Used to treat gout
Cytochalasins [7]	Actin	Prevents polymerization	None
Demecolcine [1]	Microtubule	Depolymerizes	Chemotherapy
Latrunculin [12]	Actin	Prevent polymerization, enhance depolymerisation	None
Jasplakinolide [13] [14]	Actin	Enhances polymerization	None
Nocodazole [4]	Microtubule	Prevents polymerization	None
Paclitaxel (taxol) [15]	Microtubule	Stabilizes microtubules and therefore prevents mitosis	Chemotherapy
Phalloidin [16]	Actin	Stabilizes filaments	None
Swinholide [17]	Actin	Sequesters actin dimers	None
Vinblastine [1]	Microtubule	Prevents polymerization	Chemotherapy
Rotenone [5]	Microtubule	Prevents polymerization	Pesticide

See also

• Actin-binding protein

References

1. Jordan MA, Wilson L (April 2004). "Microtubules as a target for anticancer drugs". Nature Reviews. Cancer. 4 (4): 253–65. doi:10.1038/nrc1317. PMID   15057285. S2CID   10228718.
2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (May 1971). "Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia". Journal of the American Chemical Society. 93 (9): 2325–7. doi:10.1021/ja00738a045. PMID   5553076.
3. Vandecandelaere A, Martin SR, Engelborghs Y (April 1997). "Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules". The Biochemical Journal. 323 ( Pt 1) (Pt 1): 189–96. doi:10.1042/bj3230189. PMC   1218294 . PMID   9173881.
4. Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L (June 1997). "Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro". Molecular Biology of the Cell. 8 (6): 973–85. doi:10.1091/mbc.8.6.973. PMC   305707 . PMID   9201709.
5. Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H (April 2017). "Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation". Scientific Reports. 7: 45465. Bibcode:2017NatSR...745465H. doi:10.1038/srep45465. PMC   5379642 . PMID   28374803.
6. Lodish H (2016). Molecular Cell Biology. Macmillan Learning. pp. 791–792. ISBN   978-1-464-18745-2.
7. Cooper JA (October 1987). "Effects of cytochalasin and phalloidin on actin" (PDF). The Journal of Cell Biology. 105 (4): 1473–8. doi:10.1083/jcb.105.4.1473. PMC   2114638 . PMID   3312229.
8. Lodish H (2016). Molecular Cell Biology. Macmillan Learning. p. 781. ISBN   978-1-464-18745-2.
9. Lodish H (2016). Molecular Cell Biology. Macmillian Learning. p. 782. ISBN   978-1-464-18745-2.
10. Garcia J, Costa VM, Carvalho A, Baptista P, de Pinho PG, de Lourdes Bastos M, Carvalho F (December 2015). "Amanita phalloides poisoning: Mechanisms of toxicity and treatment". Food and Chemical Toxicology. 86: 41–55. doi:10.1016/j.fct.2015.09.008. hdl: 10198/17717 . PMID   26375431.
11. Vandecandelaere A, Martin SR, Engelborghs Y (April 1997). "Response of microtubules to the addition of colchicine and tubulin-colchicine: evaluation of models for the interaction of drugs with microtubules". The Biochemical Journal. 323 ( Pt 1) (Pt 1): 189–96. doi:10.1042/bj3230189. PMC   1218294 . PMID   9173881.
12. Yarmola EG, Somasundaram T, Boring TA, Spector I, Bubb MR (September 2000). "Actin-latrunculin A structure and function. Differential modulation of actin-binding protein function by latrunculin A". The Journal of Biological Chemistry. 275 (36): 28120–7. doi: 10.1074/jbc.M004253200 . PMID   10859320.
13. Sasse F, Kunze B, Gronewold TM, Reichenbach H (October 1998). "The chondramides: cytostatic agents from myxobacteria acting on the actin cytoskeleton". Journal of the National Cancer Institute. 90 (20): 1559–63. doi: 10.1093/jnci/90.20.1559 . PMID   9790549.
14. Bubb MR, Spector I, Beyer BB, Fosen KM (February 2000). "Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations". The Journal of Biological Chemistry. 275 (7): 5163–70. doi: 10.1074/jbc.275.7.5163 . PMID   10671562.
15. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (May 1971). "Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia". Journal of the American Chemical Society. 93 (9): 2325–7. doi:10.1021/ja00738a045. PMID   5553076.
16. Buchwalow, Igor B.; Böcker, Werner (2010). Immunohistochemistry: Basics and Methods . Springer. pp.  92. ISBN   978-3-642-04608-7.
17. Bubb MR, Spector I, Bershadsky AD, Korn ED (February 1995). "Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments". The Journal of Biological Chemistry. 270 (8): 3463–6. doi: 10.1074/jbc.270.8.3463 . PMID   7876075.